GENEREX BIOTECHNOLOGY CORP
DelistedCIK 1059784fmd_1RSERRPVGM36B8D9791ZNWDYAAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Aug 02, 1995 to Apr 30, 2021, 58 periods
Latest annual · FY2020
Millions- Total revenues
- 3
- Gross profit
- 2
- Operating income
- (18)
- Net income
- (34)
- Free cash flow
- (6)
Latest quarter · Q3 FY2021
Millions- Total revenues
- 0
- Gross profit
- (0)
- Operating income
- (6)
- Net income
- 8
- Free cash flow
- 1
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2017 to FY2020
- n/m
- Revenue, 5 yearsFY2015 to FY2020
- n/m
- Net income, 5 yearsFY2015 to FY2020
- n/m
GENEREX BIOTECHNOLOGY CORP financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Revenue | $2.7 million | $6.2 million | -57.1% | 10-K 2020-11-13 · proof |
| Gross profit | $2.1 million | $2.1 million | +0.8% | 10-K 2020-11-13 · proof |
| Operating income | -$17.9 million | -$24.3 million | 10-K 2020-11-13 · proof | |
| Net income | -$34.2 million | -$11 million | 10-K 2020-11-13 · proof | |
| Cash from operating activities | -$6.1 million | -$9.6 million | 10-K 2020-11-13 · proof | |
| Free cash flow | -$6.1 million | -$9.9 million | 10-K 2020-11-13 · proof | |
| Total assets | $45.4 million | $49.6 million | -8.6% | 10-K 2020-11-13 · proof |
| Total liabilities | $53.3 million | $37.9 million | +40.6% | 10-K 2020-11-13 · proof |
| Cash and cash equivalents | $15,452 | $298,485 | -94.8% | 10-K 2020-11-13 · proof |
- What was GENEREX BIOTECHNOLOGY CORP's revenue in fiscal 2020?
- GENEREX BIOTECHNOLOGY CORP reported revenue of $2.7 million for fiscal 2020 (the year ended Jul 31, 2020), against $6.2 million the year before (-57.1%). Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What was GENEREX BIOTECHNOLOGY CORP's gross profit in fiscal 2020?
- GENEREX BIOTECHNOLOGY CORP reported gross profit of $2.1 million for fiscal 2020 (the year ended Jul 31, 2020), against $2.1 million the year before (+0.8%). Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What was GENEREX BIOTECHNOLOGY CORP's operating income in fiscal 2020?
- GENEREX BIOTECHNOLOGY CORP reported operating income of -$17.9 million for fiscal 2020 (the year ended Jul 31, 2020), against -$24.3 million the year before. Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What was GENEREX BIOTECHNOLOGY CORP's net income in fiscal 2020?
- GENEREX BIOTECHNOLOGY CORP reported net income of -$34.2 million for fiscal 2020 (the year ended Jul 31, 2020), against -$11 million the year before. Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What was GENEREX BIOTECHNOLOGY CORP's cash from operating activities in fiscal 2020?
- GENEREX BIOTECHNOLOGY CORP reported cash from operating activities of -$6.1 million for fiscal 2020 (the year ended Jul 31, 2020), against -$9.6 million the year before. Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What was GENEREX BIOTECHNOLOGY CORP's free cash flow in fiscal 2020?
- GENEREX BIOTECHNOLOGY CORP reported free cash flow of -$6.1 million for fiscal 2020 (the year ended Jul 31, 2020), against -$9.9 million the year before. Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What are GENEREX BIOTECHNOLOGY CORP's total assets?
- As of Jul 31, 2020, GENEREX BIOTECHNOLOGY CORP reported total assets of $45.4 million, against $49.6 million a year earlier (-8.6%). Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What are GENEREX BIOTECHNOLOGY CORP's total liabilities?
- As of Jul 31, 2020, GENEREX BIOTECHNOLOGY CORP reported total liabilities of $53.3 million, against $37.9 million a year earlier (+40.6%). Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
- What are GENEREX BIOTECHNOLOGY CORP's cash and cash equivalents?
- As of Jul 31, 2020, GENEREX BIOTECHNOLOGY CORP reported cash and cash equivalents of $15,452, against $298,485 a year earlier (-94.8%). Source: the 10-K filed with the SEC on Nov 13, 2020. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1059784&period_type=annual&limit=5"Information only, not investment advice.